Enzon Pharmaceuticals, Inc. Stock Other OTC
Equities
ENZN
US2939041081
Biotechnology & Medical Research
Sales 2022 | 26K 35.54K | Sales 2023 | - | Capitalization | 6.94M 9.49M |
---|---|---|---|---|---|
Net income 2022 | - 0 | Net income 2023 | 1M 1.37M | EV / Sales 2022 | -1,103 x |
Net cash position 2022 | 46.98M 64.22M | Net cash position 2023 | 47.01M 64.26M | EV / Sales 2023 | - |
P/E ratio 2022 |
-12.5
x | P/E ratio 2023 |
70.9
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 89.16% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 80 | 13-12-12 |
Members of the board | Title | Age | Since |
---|---|---|---|
Randolph Read
CHM | Chairman | 71 | 20-08-03 |
Director/Board Member | 67 | 22-06-30 | |
Jordan Bleznick
BRD | Director/Board Member | 68 | 20-08-03 |
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |